Earnings ·
Foghorn Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing collaboration…
FHTXFoghorn Therapeutics Inc.
Foghorn Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing collaboration revenue of $16.1 million and a net loss of $7.2 million. The company holds approximately $168 million in cash equivalents, providing a runway into the first half of 2028. Clinically, the Phase 1 dose-escalation trial for FHD-909 (LY4050784) is advancing as planned with non-small cell lung cancer as the primary target population. The company also announced that IND submissions are targeted for 2027 for a novel oral small molecule in immunology and inflammation, as well as its selective EP300 degrader program. Foghorn Therapeutics operates in the biotechnology industry, developing medicines targeting chromatin biology.